Macular Degeneration Treatment Market Size, Share & Trends Analysis Report By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD), By Route of Administration (Intravenous Route, Intravitreal Route), By Sales Channels (Ambulatory Surgical Centers, Hospitals, Other Sales Channels) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Macular Degeneration Treatment Market Size

The global macular degeneration treatment market size was valued at USD 16.7 billion in 2025 and is projected to grow from USD 18.07 billion in 2026 to USD 33.89 billion by 2034, registering a CAGR of 8.18% during the forecast period from 2026 to 2034. North America dominated the macular degeneration treatment market with a market share of 41.5% in 2025.

Factors such as rising impact of retinal disorders and improving investments in research and development significantly drives the macular degeneration treatment market demand by 2033. Macular degeneration causes loss of central vision since it gives the clear, central vision required to see objects. The eye's macula is impacted by macular degeneration, a neurological disorder. It manifests when the capillaries close to the fovea expand and leak. The fluid buildup interferes with light reflection, which causes progressive vision loss. Most in danger are people between the ages of 50 and 60. The symptoms of this illness include night blindness, tunnel vision, and loss of central vision, also called age-related macular degeneration (AMD).

Nutritional therapy can aid treatment in the early stages of dry macular degeneration. A healthy diet rich in antioxidants is part of the plan to sustain the macula's cells. Supplements to improve the number of particular vitamins and minerals that could increase healthy pigments and promote cell structure are given if macular degeneration is advanced but still dry.

Type Insights

The global market for macular degeneration treatment is bifurcated into dry and wet age-related macular degeneration. The wet age-related macular degeneration segment is the highest contributor to the market and is expected to grow at a CAGR of 6.98% over the forecast period. Wet macular degeneration is marked by aberrant blood vessels under the retina and macula, known as choroidal neovascularization or CNV. The macula may then bulge or lift from its typically flat position due to these new blood vessels bleeding and leaking fluid, blurring, or impairing central vision. Wet macular degeneration accounts for around 10% of cases but results in 90% of legal blindness. The dry form of the disease always comes before wet macular degeneration. Wet macular degeneration is treatable if identified early. Medications are injected into the eye to stop the development of abnormal blood vessels.

One of the most common eye conditions affecting people 50 years or older is dry macular degeneration. Blurred or reduced center vision is the result of the macula's thinning. The macula provides a clear idea in a straight line of sight, a retina component. According to the American Academy of Ophthalmology, the dry form of AMD affects about 80% (8 out of 10) of AMD patients. Dry macular degeneration can progress and impair vision without developing into the wet form of the condition. However, early dry age-related macular degeneration may suddenly transform into the wet variety. There is currently no treatment to stop further vision loss once dry AMD reaches the advanced stage. Intervention strategies, on the other hand, might postpone or even halt intermediate AMD from progressing to the advanced stage, where vision loss occurs.

Request Customizationto receive a tailored report.

Stage of Disease Insights

The global market for macular degeneration treatment is bifurcated into early-stage AMD, intermediate AMD, and late-stage AMD. The late-stage AMD segment owns the highest market share and is expected to grow at a CAGR of 7.03% during the forecast period. Macular degeneration-related vision loss peaks in late-stage AMD, though not all cases of early AMD progress to late AMD. Geographic atrophy (also known as Dry AMD) and neovascular AMD (also known as Wet AMD/nvAMD) are the two different types of late-stage AMD. The macula and the tissue that supports it both deteriorate in dry AMD. Under the retina, abnormal blood vessel growth is a symptom of wet AMD. The macula may become damaged if these vessels leak. Although less common than dry AMD, wet AMD poses a greater risk to vision. Many medical procedures are now being created or studied to discover if they are effective. As a result, the availability of approved and in-development therapies is anticipated to broaden patients' options and raise demand for these treatments.

There may be some vision loss at the intermediate AMD stage, but no apparent symptoms exist. During a complete eye exam, specific tests may be used to look for larger drusen and pigment changes in the retina. The focus of recommendations for patients with intermediate AMD is assessing and addressing risk factors, notably quitting smoking and taking antioxidant supplements. However, it is crucial to inform the patient that an immediate appointment with an ophthalmologist is required if they notice a sudden change in their vision. The advantages of antioxidant therapy (i.e., vitamin E, vitamin C, lutein and zeaxanthin, zinc, and copper) in the intermediate AMD stage are consistently supported by various studies.

Route of Administration Insights

The global macular degeneration treatment industry is bifurcated into the intravenous route and intravitreal route. The intravitreal route segment is the highest contributor to the market and is expected to grow at a CAGR of 7.10% during the forecast period. A highly targeted drug therapy is made possible by intravitreal injection, which maximizes therapeutic drug delivery to the posterior pole and reduces systemic toxicity. The intravitreal injection has become the most frequent ophthalmic procedure due to the growing use of intravitreal anti-VEGF (vascular endothelial growth factor) agents in treating neovascular age-related macular degeneration (AMD). Currently, the most common and effective clinical treatment for wet AMD is anti-VEGF medication, which is frequently administered intravitreally.

Visudyne is injected intravenously to direct the laser during photodynamic therapy (PDT). A low-level, non-thermal laser activates Visudyne medication. Wet macular degeneration photodynamic treatment reduces abnormal blood vessel growth and macula bleeding. The process stops leaking vessels while protecting healthy ones, improving earlier laser treatments. The results of future field studies should be fruitful, which could help future market expansion.

Sales Channel Insights

The global macular degeneration treatment industry is bifurcated into ambulatory surgical centers and hospitals. The hospital segment owns the highest market share and is expected to grow at a CAGR of 7.04% during the forecast period. Inpatients at tertiary hospitals often request ophthalmology consultations. Examining hospital inpatients is more complex than outpatients. Ophthalmologists provide eye care, treat acute eye conditions, and perform emergency and elective ophthalmic surgery. They also offer inpatient consultation services in evaluating and treating diseases that threaten vision and contribute to diagnosing a systemic disease that affects other hospital departments and units. Inpatient care is more extended, which may be beneficial if complications worsen, despite the higher procedure and hospital costs.

Medical care or treatment that does not necessitate an overnight stay in a hospital or other healthcare facility is called outpatient care, also known as ambulatory care. Outpatient care is often provided in one of these locations or an outpatient surgery facility, though it can also be provided in a hospital or doctor's office. One of the treatments for macular degeneration is laser photocoagulation surgery, typically performed as an outpatient procedure. The eye is numbed before the outpatient procedure, and abnormal leaky blood vessels are sealed and destroyed by a high-energy laser. The market is anticipated to grow as ambulatory care is in higher demand and centers offer additional advantages.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant shareholder in the global market for macular degeneration treatment and is expected to grow at a CAGR of 7.10% during the forecast period. Due to several factors, including the growing burden of the elderly population and the prevalence of age-related macular degeneration, the United States accounts for a sizeable portion of the market under study. The US is committed to enhancing population eye health through several initiatives. Additionally, it is anticipated that the key market players' presence, along with recent product launches and established healthcare infrastructure, will accelerate the market's growth in the United States. The market development under study in the United States is anticipated to be fueled by novel treatments for macular degeneration.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe: Rapidly Growing Region

Europe is expected to grow at a CAGR of 6.70%, generating USD 3,531.14 million during the forecast period. The factors driving the expansion of the French macular degeneration treatment industry include the aging population, the growing macular degeneration burden, and significant R&D investments. A growing number of advanced research studies are being conducted in France. This is mainly because of the funding provided by the government, both at the national and EU agency levels. In France, which has one of the best healthcare systems, the government and the individual is responsible for paying for medical expenses. These campaigns are anticipated to raise public awareness and lead to rapid market growth in France over the forecast period.

Asia-Pacific Macular Degeneration Treatment Market

In Asia-Pacific, the growing awareness of macular degeneration, the presence of key market players, and the rising elderly population in Japan all point to significant growth in the Japanese market for macular degeneration treatments. Japan is one of the Asian countries with a rapidly aging population. Sumitomo Dainippon Pharma Co. Ltd. amended its agreement with Healios K.K. for joint development programs and other joint activities in Japan in June 2019. The amendments related to the development and commercialization activities. In order to treat age-related macular degeneration and other eye diseases, joint development activities will concentrate on retinal pigment epithelial cells derived from iPS cells. The market for macular degeneration treatments in Japan is anticipated to grow due to rising AMD prevalence and R&D efforts in the field.

Middle East and Africa Trends

In the Middle East and Africa, Saudi Arabia, Kuwait, Bahrain, Qatar, the UAE, and Oman make up the Gulf Cooperation Council (GCC). The GCC is increasing healthcare investments as patient volume and data grow. The GCC's growing disease burden and privatization have boosted the market for macular degeneration treatments. Due to population growth, AMD is the fastest-growing ophthalmological concern in the Gulf. According to the World Population Ageing 2019 report, Saudi Arabia had 1.169 million (3.4%) 65-plus persons in 2019, with a projected increase to 7.689 million (17.2%) by 2050. The market is expected to grow because the elderly are more susceptible to ophthalmic disorders like AMD. Rising R&D for novel drugs, market penetration by major players, and healthcare initiatives are also driving the GCC macular degeneration market.

List of Key and Emerging Players in Macular Degeneration Treatment Market